Letters sent to healthcare professionals in April 2015

Last month, letters were sent regarding ketoprofen gel, fingolimod (Gilenya▼) and efavirenz (Sustiva).

From:
Medicines and Healthcare products Regulatory Agency
Published
20 May 2015
Therapeutic area:
Dermatology, Immunosuppression and transplantation, Infectious disease, Neurology, Paediatrics and neonatology, Rheumatology

In each issue of Drug Safety Update we summarise drug safety letters sent to healthcare professionals that are not linked to their own Drug Safety Update article. In April 2015, letters were sent regarding:

  • Ketoprofen gel and risk of photosensitivity reactions: reminder of risk minimisation measures– sent on 20 April 2015
  • Efavirenz (Sustiva): discontinuation of the Sustiva 30 mg/ml oral solution formulation by the end of October 2015 – sent by Bristol-Myers Squibb on 23 April 2015
  • Fingolimod (Gilenya ▼): first reported case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient taking fingolimod without previous treatment with natalizumab or other immunosuppressive medicines– sent by Novartis on 29 April 2015

Article citation: Drug Safety Update volume 8 issue 10 May 2015: 4

Published 20 May 2015